Lexeo Therapeutics Inc LXEO

US Biotechnology

$3.31 ▼ -2.36% ($-0.08)

🔥 High Short Interest

Open $3.40

Prev Close $3.39

Day Range $3.27 – $3.46

52W Range $3.33 – $10.99

Market Cap $271.71M

Beta 1.60

EPS (TTM) $-1.16

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2023-11-03
Shares Out.	78,520,000
Website	lexeotx.com/ ↗
Phone	12125479879
Employees	59
Revenue	$0
Gross Profit	$0
Net Income	-$25.9M
Free Cash Flow	-$88.7M
Total Assets	$254.9M
Total Liabilities	$19.8M
Equity	$235.1M

About Lexeo Therapeutics Inc

Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.

Lexeo Therapeutics Inc is a publicly traded company under the ticker symbol LXEO on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.